Very short, tissue-specific peptides proposed to regulate gene expression — the Khavinson series, read with the evidence in full view.
Bioregulators are the shortest peptides in this catalog — di-, tri-, and tetrapeptides developed largely by the St. Petersburg Institute of Bioregulation and Gerontology (the "Khavinson" school). Each is associated with a specific tissue and proposed to act not as a hormone or receptor ligand but as a direct regulator of gene expression. The class is popular in longevity circles and unusually thin on independent Western data, which is exactly why it belongs here framed honestly rather than promotionally. This is a mechanistic research reference, not medical, dosing, or purchasing guidance.
The class began with tissue extracts. Thymalin, a polypeptide fraction of thymus, was the prototype "Cytomax" — an animal-tissue extract intended to bioregulate the organ it came from. The defined synthetic short peptides that followed (the "Cytogens") were modeled on these extracts: Vilon (Lys-Glu) as a defined stand-in for Thymalin, then a family of organ-specific sequences — Epitalon (pineal), Vesugen (vascular), Pinealon (brain), Bronchogen (lung), Cardiogen (heart), Pancragen (pancreas).
The central hypothesis is gene-regulatory rather than receptor-mediated. Because these peptides are so small, the originating group proposed that they enter the cell, reach the nucleus, and bind specific promoter sequences in DNA — de-condensing heterochromatin and switching on tissue-relevant genes that fall silent with age. Tissue selectivity, in this model, comes from sequence-specific DNA contacts rather than from a cell-surface receptor. This mechanism is proposed and partially supported in the originating literature, not firmly established by independent structural work.
The honest caveat is the point, not a footnote. Nearly all of the clinical and lifespan data come from a single research tradition, much of it older, Russian-language, and not independently replicated in large Western trials. Epitalon's telomerase and lifespan claims in particular outrun the third-party evidence. For a trust-first reference the value-add is exactly this: clear sequences, a sober evidence grade, and identity/purity scrutiny for a category where short, cheap peptides are easy to misrepresent.
Synthetic tetrapeptide investigated for telomerase activity and circadian effects.
View profileThe natural pineal peptide bioregulator — the animal-derived counterpart to synthetic Epitalon, marketed for aging and telomere support.
View profileThymus-derived polypeptide complex — the founding tissue bioregulator (Cytomax) studied for immune restoration.
View profileA synthetic thymic dipeptide (Glu-Trp) immunomodulator — the minimal active fragment distilled from thymus peptides.
View profileSynthetic Lys-Glu dipeptide — the defined short-peptide successor to Thymalin, studied for immune and aging endpoints.
View profileSynthetic Lys-Glu-Asp tripeptide studied as a vascular-axis bioregulator.
View profileSynthetic Glu-Asp-Arg tripeptide studied as a brain/CNS bioregulator.
View profileSynthetic Ala-Asp-Glu-Leu tetrapeptide studied as a respiratory-tissue bioregulator.
View profileSynthetic Ala-Glu-Asp-Arg tetrapeptide studied as a cardiac-tissue bioregulator.
View profileSynthetic Lys-Glu-Asp-Trp tetrapeptide studied as a pancreas-tissue bioregulator.
View profileSynthetic Lys-Glu-Asp-Gly tetrapeptide studied as a testis / reproductive-tissue bioregulator.
View profileSynthetic Lys-Glu-Asp-Pro tetrapeptide studied as a prostate-tissue bioregulator — the defined-sequence successor to older prostate extracts.
View profileA natural thymus peptide complex (Cytomax A-6) — the extract-based counterpart to Thymalin, marketed for immune support and aging.
View profileA natural blood-vessel peptide complex (Cytomax A-3) — the extract-based counterpart to Vesugen, targeting vascular tissue.
View profileA natural heart-muscle peptide complex (Cytomax A-14) — the extract-based counterpart to Cardiogen, targeting cardiac tissue.
View profileIn this catalog, a bioregulator is a very short, tissue-specific peptide — usually 2 to 4 amino acids — from the Khavinson Cytomax/Cytogen series, proposed to regulate gene expression in a particular organ rather than act as a hormone. Entries are mechanistic reference profiles, not products or treatment recommendations.
It is a class (short tissue-regulating peptides), not an indication, so its members are cross-listed by what they are studied for — Epitalon and Vilon also appear under longevity and immune. This page organizes them by the shared bioregulator hypothesis and history.
Weaker and narrower than the popularity suggests. Most clinical and lifespan data come from a single research tradition with limited independent Western replication, so findings should be treated as preliminary. We flag this on every entry rather than burying it.
No. AmericanPeptide.com is a computational research and reference platform, not a medical device or clinical decision-support system. Nothing here is medical advice, a dosing protocol, or an offer to sell. Independent expert and regulatory review is required before any experimental use.